Sfoglia per AUTORE
COSCIA M
Collezione ASL Asti

  

Items : 10

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. in Hematological oncology / Hematol Oncol. 2021 Aug;39(3):326-335. doi: 10.1002/hon.2861. Epub 2021 Mar 26.

2021
ASL Asti
AOU Città della Salute di Torino
AOU Novara

Foà R; Cuneo A; Vignetti M; Gentile M; Montillo M; Marchetti M; Mauro FR; Crea E; Marasca R; Quaglia FM; Laurenti L; Molinari AL; Paolini R; Pietrasanta D; Sportoletti P; Varettoni M; Farina L; Murru R; Gaidano G; Cibien F; Vitagliano O; Coscia M; Zamprogna G; Visentin A; Reda G; Arena V; Cavazzini F; Piciocchi A; Rigolin GM; et alii...

OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY in Haematologica

2021
ASL Asti

Visentin A; Pravato S; Mauro FR; Pietrasanta D; Fresa A; Vitale C; Ciolli S; Cassin R; Cibien F; Sportoletti P; Gentile M; Rigolin GM; Quaglia FM; Murru R; Gozzetti A; Molica S; Marchetti M; Scarfò L; Guardalben E; Avitabile A; Reda G; Coscia M; Laurenti L; Pizzolo G; Semenzato G; Foà R; Cuneo A; Trentin L;

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. in Cancer medicine / Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.

2020
ASL Asti
AOU Città della Salute di Torino

Foà R; Ghia P; Cucci R; Vignetti M; Cavallari M; Cimino G; Ferrarini I; de la Serna J; Medina Perez A; Mauro FR; Di Raimondo F; Coscia M; Molica S; Farina L; Doubek M; Gaidano G; Ilariucci F; Marchetti M; Tedeschi A; Spacek M; Trentin L; Billio A; Roeker L; Orlandi EM; Ujjani CS; Shah NN; Sehgal AR; Schuster SJ; Pu JJ; et alii...

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino

Coscia M; Foà R; Massaia M; Gaidano G; Bernardi R; Gattei V; Zenz T; Mauro FR; Del Poeta G; Laurenti L; Omedè P; Kodipad AA; Marchetti M; Bonello L; Magliulo D; Bo MD; Pozzato G; Rossi D; Bomben R; Riganti C; Salvetti C; Kopecka J; Todaro M; Vitale C; Griggio V; Boccadoro M;

Worldwide Examination of Patients with CLL Hospitalized for COVID-19 in Blood

2020
ASL Asti

Roeker LE; Scarfo L; Chatzikonstantinou T; Abrisqueta P; Eyre TA; Cordoba R; Muntañola Prat A; Villacampa G; Leslie LA; Koropsak M; Quaresmini G; Allan JN; Furman RR; Bhavsar EB; Pagel JM; Hernandez-Rivas JA; Patel K; Motta M; Bailey N; Miras F; Lamanna N; Alonso R; Osorio-Prendes S; Vitale C; Kamdar M; Baltasar P; Österborg A; Hanson L; Baile M; et alii...

Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus in Blood

2020
ASL Asti

Visentin A; Mauro FR; Pietrasanta D; Fresa A; Vitale C; Ciolli S; Cassin R; Cibien F; Sportoletti P; Gentile M; Rigolin GM; Quaglia FM; Murru R; Gozzetti A; Molica S; Marchetti M; Scarfo L; Reda G; Coscia M; Laurenti L; Pizzolo G; Semenzato G; Foà R; Cuneo A; Trentin L;

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia in Haematologica

2020
ASL Asti

Griggio V; Vitale C; Todaro M; Riganti C; Kopecka J; Salvetti C; Bomben R; Bo MD; Magliulo D; Rossi D; Pozzato G; Bonello L; Marchetti M; Omedè P; Kodipad AA; Laurenti L; Poeta GD; Mauro FR; Bernardi R; Zenz T; Gattei V; Gaidano G; Foà R; Massaia M; Boccadoro M; Coscia M;

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia in Haematologica

2020
ASL Asti

Griggio V; Vitale C; Todaro M; Riganti C; Kopecka J; Salvetti C; Bomben R; Bo MD; Magliulo D; Rossi D; Pozzato G; Bonello L; Marchetti M; Omedè P; Kodipad AA; Laurenti L; Poeta GD; Mauro FR; Bernardi R; Zenz T; Gattei V; Gaidano G; Foà R; Massaia M; Boccadoro M; Coscia M;

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia in Haematologica

2020
ASL Asti

Griggio V; Vitale C; Todaro M; Riganti C; Kopecka J; Salvetti C; Bomben R; Bo MD; Magliulo D; Rossi D; Pozzato G; Bonello L; Marchetti M; Omedè P; Kodipad AA; Laurenti L; Poeta GD; Mauro FR; Bernardi R; Zenz T; Gattei V; Gaidano G; Foà R; Massaia M; Boccadoro M; Coscia M;

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. in Haematologica / Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

2018
ASL Asti
AOU Città della Salute di Torino
AOU Novara

Ghia P; Moreno C; Foà R; de la Serna J; Vignetti M; Kennedy B; Bowles KM; Eyre TA; Schuh A; Smolej L; Montillo M; Cortelezzi A; Ciolli S; Forconi F; Gonzalez M; Gaidano G; Re F; Molica S; Marchetti M; Ilariucci F; Meneghini V; Chiarenza A; Marasca R; Billio A; Visco C; Amendola A; Mauro FR; Galieni P; Orlandi EM; et alii...